The global immunoassay market, poised to grow from USD 35.5 billion in 2025 to USD 47.7 billion by 2030, is propelled by rising chronic and infectious diseases, technological advancements, and regulatory demands for drug testing. Dominating products include reagents and kits, crucial for diagnostics. Chemiluminescence immunoassays (CLIA) are anticipated to grow rapidly, offering superior diagnostic capabilities. Infectious diseases drive the application market, with Asia Pacific leading regional growth due to expanding health infrastructure and disease prevalence.
Dublin, Dec. 08, 2025 (GLOBE NEWSWIRE) -- The "Immunoassay Market by Product (Reagents & Kits, Analyzers), Technology (ELISA, CLIA, Western Blot), Specimen (Blood, Saliva, Urine), Application (Infectious Diseases, Endocrinology), End User (Hospitals & Clinics, Laboratories) - Global Forecast to 2030" has been added to ResearchAndMarkets.com's offering.
The global immunoassay market is set to expand from an estimated USD 35.5 billion in 2025 to USD 47.7 billion by 2030, at a CAGR of 6.1%. Growth factors include rising chronic and infectious diseases, advancements in immunoassay systems, beneficial government policies, and stringent regulations for drug and alcohol testing.

Reagents & Kits Lead the Market
Reagents & kits dominate the immunoassay products market, driven by their frequent use in diverse diagnostic assays and growing demand due to increased immunoassay procedures globally. High-performance reagents and kits have introduced precision and efficiency, enhancing their adoption.
CLIA Technology to Experience Growth
The immunoassay market classifies technologies into ELISA, CLIA, IFA, rapid tests, ELISpot, western blotting, and others. CLIA is expected to grow significantly, offering advanced diagnostic capabilities and superior sensitivity, range, and specificity compared to traditional methods like ELISA, making CLIA a preferred choice in clinical diagnostics.
Dominance of Infectious Disease Applications
The immunoassay market is segmented by application, including infectious diseases, cardiology, endocrinology, oncology, and others. In 2022, infectious diseases dominated due to rising cases of HIV/AIDS, hepatitis, and influenza. Immunoassays have enhanced rapid diagnostic capability, crucial for managing infectious disease outbreaks.
Rapid Growth in Asia Pacific
The Asia Pacific region is projected to be the fastest-growing market, supported by a large patient base, rising chronic disease prevalence, increased awareness of early diagnosis, and advancements in healthcare, particularly in China, India, and Southeast Asia.
Key Industry Participants
Key Insights
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 494 |
| Forecast Period | 2025 - 2030 |
| Estimated Market Value (USD) in 2025 | $35.5 Billion |
| Forecasted Market Value (USD) by 2030 | $47.7 Billion |
| Compound Annual Growth Rate | 6.1% |
| Regions Covered | Global |
Company Profiles
For more information about this report visit https://www.researchandmarkets.com/r/9m7i28
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900